228 related articles for article (PubMed ID: 31969230)
1. Recommendations in clinical practice guidelines on gout: systematic review and consistency analysis.
Yu Y; Wang D; Zhou Q; Wang C; Ma X; Gao Y; Song X; Xiao S; Wang Q; Zeng X; Estill J; Qian Z; Chen Y
Clin Exp Rheumatol; 2020; 38(5):964-972. PubMed ID: 31969230
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.
Li Q; Li X; Wang J; Liu H; Kwong JS; Chen H; Li L; Chung SC; Shah A; Chen Y; An Z; Sun X; Hemingway H; Tian H; Li S
BMJ Open; 2019 Aug; 9(8):e026677. PubMed ID: 31446403
[TBL] [Abstract][Full Text] [Related]
3. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Quality of Global Clinical Practice Guidelines on Gout Using AGREE II Instrument.
Wang D; Yu Y; Chen Y; Yang N; Zhang H; Wang C; Wang Q; Wang X; Zeng X; Estill J
J Clin Rheumatol; 2020 Mar; 26(2):54-59. PubMed ID: 32073515
[TBL] [Abstract][Full Text] [Related]
5. An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout.
Nuki G
Curr Opin Rheumatol; 2014 Mar; 26(2):152-61. PubMed ID: 24492863
[TBL] [Abstract][Full Text] [Related]
6. [Gout management: an update].
Ankli B; Krähenbühl S
Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
[TBL] [Abstract][Full Text] [Related]
7. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).
Dalbeth N; Bardin T; Doherty M; Lioté F; Richette P; Saag KG; So AK; Stamp LK; Choi HK; Terkeltaub R
Nat Rev Rheumatol; 2017 Sep; 13(9):561-568. PubMed ID: 28794514
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
9. What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines.
Conley B; Bunzli S; Bullen J; O'Brien P; Persaud J; Gunatillake T; Dowsey MM; Choong PF; Nikpour M; Grainger R; Lin I
BMC Rheumatol; 2023 Jun; 7(1):15. PubMed ID: 37316871
[TBL] [Abstract][Full Text] [Related]
10. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
Latourte A; Bardin T; Richette P
Rheumatology (Oxford); 2014 Nov; 53(11):1920-6. PubMed ID: 24758886
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
Schlesinger N
Semin Arthritis Rheum; 2012 Oct; 42(2):155-65. PubMed ID: 22542277
[TBL] [Abstract][Full Text] [Related]
15. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
Stevenson M; Pandor A
Pharmacoeconomics; 2011 Feb; 29(2):133-40. PubMed ID: 21155617
[TBL] [Abstract][Full Text] [Related]
17. [Gout].
Tausche AK
Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
[TBL] [Abstract][Full Text] [Related]
18. Reporting, presentation and wording of recommendations in clinical practice guideline for gout: a systematic analysis.
Yang N; Yu Y; Zhang A; Estill J; Wang X; Zheng M; Zhou Q; Zhang J; Luo X; Qian C; Mao Y; Wang Q; Yang Y; Chen Y
BMJ Open; 2019 Jan; 9(1):e024315. PubMed ID: 30700479
[TBL] [Abstract][Full Text] [Related]
19. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
